**FOR IMMEDIATE RELEASE**

FOR IMMEDIATE RELEASE

WASHINGTON D.C. – A new pharmaceutical initiative, dubbed “TrumpRx,” has been unveiled by former President Donald J. Trump, promising to radically overhaul prescription drug pricing in the United States.

WHO: Former President Donald J. Trump, alongside a coalition of private sector healthcare investors and independent pharmacy owners.

WHAT: The launch of “TrumpRx,” a private-sector plan aimed at reducing the cost of generic and brand-name medications through a tiered discount model. The initiative claims to bypass traditional pharmacy benefit managers (PBMs) by negotiating directly with drug manufacturers.

WHEN: The formal announcement was made earlier today via a press conference at Trump Tower. Pre-enrollment for the program is scheduled to begin on March 1, 2025.

WHERE: The program is initially limited to 12 states, with a national rollout contingent on regulatory approval and contractual agreements. Full details on participating states were not immediately released.

WHY: According to the former President, the primary goal is to combat what he termed “PBM price gouging” and provide “transparent, low-cost prescriptions” directly to American consumers. Critics, however, have raised concerns over the lack of federal oversight and potential conflicts of interest involving the former President’s business partners.

WHAT NOW: Pharmaceutical industry analysts are currently scrutinizing the plan’s sustainability, while the White House has issued a statement calling the initiative a “dangerous privatization of healthcare policy.”